M&A remains a vital tool for health industries companies, enabling them to drive business transformation and deliver sustained outcomes by creating value over the long term. Despite regulatory frictions, M&A activity in health industries will remain robust, with the potential for acceleration in the second half of 2023 as valuation gaps between buyers and sellers begin to narrow and companies pursue innovative tech and AI-powered solutions to meet their strategic and operational challenges. Dealmakers should prepare for a more dynamic second half of 2023. See Global M&A trends (Health Industries) for PwC’s M&A outlook report.
At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 152 countries with nearly 328,000 people who are committed to delivering quality in assurance, advisory and tax services, including over 5,300 at PwC Netherlands.
Our multidisciplinary Pharma, Lifesciences and Medtech team brings together a broad spectrum of dedicated professionals to advise you throughout the entire life-cycle, from innovation to regulation, digitisation and beyond. Find out more and tell us what matters to you by visiting us at www.pwc.nl/pharma.